Trials / Completed
CompletedNCT02559895
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 898 (actual)
- Sponsor
- Alder Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALD403 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2017-02-01
- Completion
- 2017-12-01
- First posted
- 2015-09-25
- Last updated
- 2020-05-14
- Results posted
- 2020-05-14
Locations
87 sites across 2 countries: United States, Georgia
Source: ClinicalTrials.gov record NCT02559895. Inclusion in this directory is not an endorsement.